Brain Cancer Market Expected to rise, 2034 | Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffm

The Brain Cancer market growth is driven by factors like increase in the prevalence of Brain Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Brain Cancer market report [https://www.delveinsight.com/report-store/brain-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Brain Cancer market size, share, Brain Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Brain Cancer market size growth forward.

Some of the key highlights from the Brain Cancer Market Insights Report:

*
Several key pharmaceutical companies, including Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy's Laboratories Ltd, and others, are developing novel products to improve the Brain Cancer treatment outlook.

*
In January 2025, the FDA granted breakthrough device designation to CergenX's AI-driven tool, Wave, for neonatal brain scans. This designation will allow the Irish startup to receive prioritized review and enhanced communication with FDA experts during the premarket review process.

*
In December 2024, Kazia Therapeutics' stock dropped 26% to $2.28 after the FDA suggested it might consider standard approval but not accelerated approval for the company's brain cancer drug, paxalisib. Over the year, the stock has declined by approximately 48%. Paxalisib, developed for the treatment of glioblastoma, demonstrated significant overall survival benefits in a July trial, which had previously led to a surge in the company's stock.

*
The largest Brain Cancer market size in the 7MM was occupied by the US in 2023.

*
Among EU4 and the UK, Italy will capture the maximum revenue share, followed by Germany in 2034.

*
The US contributed to the largest incident-patient share, acquiring more than 38% of the 7MM in 2023.

*
Among the gender-specific cases, males are affected more than females, accounting for nearly 60% and 40% of cases respectively, in the US, in 2023.

*
Among the grade-specific cases, the cases of high-grade (III and IV) brain tumors are more incident than Low-Grade, accounting for nearly 70% of cases in the US.

*
In April 2024, the United States Food and Drug Administration (US FDA) granted accelerated approval to Day One Biopharmaceuticals' OJEMDA (tovorafenib) as a treatment for patients 6 months of age and older with certain relapsed or refractory pediatric low-grade glioma.

*
In April 2024, TME Pharma announced that the US FDA granted Fast Track Designation for NOX-A12 (olaptesed pegol), TME Pharma's CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma.

*
In February 2024, Servier announced that the US FDA accepted the filing and granted priority review for the New Drug Application (NDA) for vorasidenib, and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 20, 2024. If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas.

*
As per DelveInsight analysis, the Brain Cancer market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Brain Cancer Market Landscape [https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Brain Cancer Overview

A brain tumor, also referred to as an intracranial tumor, falls under central nervous system (CNS) tumors, which encompass a range of diseases characterized by the abnormal formation of mass lesions in the brain, spinal cord, or their protective coverings.

Brain tumors are broadly classified into two categories: primary and metastatic. Primary brain tumors are further categorized as "low grade" or "high grade." Low-grade tumors typically grow slowly but may progress into high-grade tumors over time, whereas high-grade tumors are more aggressive and tend to grow rapidly.

In adults, secondary brain tumors, also known as brain metastases, are significantly more prevalent than primary brain tumors.

Do you know the treatment paradigms for different countries? Download our Brain Cancer Market Sample Report [https://www.delveinsight.com/report-store/brain-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Brain Cancer Epidemiology Insights

*
In 2023, the United States recorded the highest number of incident cases of primary brain tumors among the 7MM, with approximately 23,000 cases. This number is anticipated to rise over the forecast period.

Brain Cancer Epidemiology Segmentation

DelveInsight's Brain Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Brain Cancer historical patient pools and forecasted Brain Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Brain Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Brain Cancer Prevalence

*
Age-Specific Brain Cancer Prevalence

*
Gender-Specific Brain Cancer Prevalence

*
Diagnosed and Treatable Cases of Brain Cancer

Visit for more @ Brain Cancer Epidemiological Insights [https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Brain Cancer Market Outlook

Brain cancer treatment typically involves a combination of therapies, including surgery, chemotherapy, radiation, and stereotactic radiosurgery, often followed by adjuvant treatments. While treatment remains largely palliative, immunotherapy has emerged as a promising approach, leveraging the body's immune system to combat tumor growth. This includes checkpoint inhibitors and cancer vaccines targeting tumor antigens, with ongoing research exploring gene and oncolytic virus therapies.

The market is highly competitive, with numerous companies actively developing new therapeutic options. The FDA's approval of OJEMDA positions it alongside Novartis' TAFINLAR-MEKINIST combination, which is currently approved for pediatric low-grade glioma (pLGG) with BRAF V600 mutations. Leading pharmaceutical companies such as Genentech, Daiichi Sankyo, Bristol Myers Squibb, Bayer, Roche, AstraZeneca, and Pfizer are advancing their brain cancer treatments in mid-to-late-stage clinical trials. Once approved, these therapies are expected to significantly impact the market landscape.

Brain Cancer Marketed Drugs

*
AVASTIN (bevacizumab): Genentech

*
TEMODAR/TEMODAL: Merck

Brain Cancer Emerging Drugs

*
Vorasidenib: Servier

*
Paxalisib: Kazia Therapeutics

Brain Cancer Key Companies

*
Y-mAbs Therapeutics Inc.

*
Shimadzu Corporation

*
Bristol-Myers Squibb

*
Bayer AG

*
AstraZeneca plc

*
Johnson & Johnson Inc.

*
Merck & Co.

*
Pfizer Inc.

*
F. Hoffmann-La Roche Ltd

*
Dr. Reddy's Laboratories Ltd, and others

For more information, visit Brain Cancer Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/brain-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Brain Cancer Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Brain Cancer, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Brain Cancer epidemiology in the 7MM

*
Brain Cancer marketed and emerging therapies

*
Brain Cancer companies

*
Brain Cancer market drivers and barriers

Table of Contents:

1 Brain Cancer Market Key Comprehensive Insights

2 Brain Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Brain Cancer

4 Brain Cancer Market Analysis Overview at a Glance

5 Executive Summary of Brain Cancer

6 Brain Cancer Epidemiology and Market Methodology

7 Brain Cancer Epidemiology and Patient Population

8 Brain Cancer Patient Journey

9 Brain Cancer Treatment Algorithm, Brain Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Brain Cancer Clinical Trials

11 Brain Cancer Marketed Therapies

12 Brain Cancer Emerging Therapies

13 Brain Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Brain Cancer

16 Brain Cancer Market Key Opinion Leaders Reviews

18 Brain Cancer Market Drivers

19 Brain Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Brain Cancer Epidemiology 2034

DelveInsight's "Brain Cancer - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Brain Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Brain Cancer Pipeline 2024

"Brain Cancer Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Brain Cancer market. A detailed picture of the Brain Cancer pipeline landscape is provided, which includes the disease overview and Brain Cancer treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=brain-cancer-market-expected-to-rise-2034-ymabs-therapeutics-inc-shimadzu-corporation-bristolmyers-squibb-bayer-ag-astrazeneca-plc-johnson-johnson-inc-merck-co-pfizer-inc-f-hoffm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.